Jing Dong, PhD

Assistant Professor

Locations

HRC 5860
Hematology and Oncology - Medicine
Cancer Prevention and Outcomes, Cancer Center
Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine

Biography

Dr. Dong is an assistant professor of medicine at the Medical College of Wisconsin, Division of Hematology and Oncology and also has a joint appointment with the Mellowes Center. Her research interests focus on integrating high-throughput “omics” data into epidemiological studies to develop approaches to reduce cancer burden and cancer disparities.

Dr. Dong received her PhD at Nanjing Medical University, China in 2012, then completed her training in epidemiology at National Institute of Environmental Health Sciences. Afterward, she was awarded by Cancer Prevention and Research Institute of Texas to join a training program in integrative cancer epidemiology at Baylor College of Medicine. Her work has led to more than 60 publications in several major high-ranking journals in cancer and genetic epidemiology areas, such as Nat Genet., Nat Commun., and Gastroenterology. She also serves as a reviewer for more than 20 international peer-reviewed journals, including but not limited to Communications Biology, Clin Gastroenterol Hepatol., Carcinogenesis, and as editorial board of BMC Cancer, Annals of Translational Medicine and Journal of Cancer Research Forecast.

Research Interests

Genetic and molecular epidemiology, Risk prediction, Cancer disparities

GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level.

(Schröder J, Chegwidden L, Maj C, Gehlen J, Speller J, Böhmer AC, Borisov O, Hess T, Kreuser N, Venerito M, Alakus H, May A, Gerges C, Schmidt T, Thieme R, Heider D, Hillmer AM, Reingruber J, Lyros O, Dietrich A, Hoffmeister A, Mehdorn M, Lordick F, Stocker G, Hohaus M, Reim D, Kandler J, Müller M, Ebigbo A, Fuchs C, Bruns CJ, Hölscher AH, Lang H, Grimminger PP, Dakkak D, Vashist Y, May S, Görg S, Franke A, Ellinghaus D, Galavotti S, Veits L, Weismüller J, Dommermuth J, Benner U, Rösch T, Messmann H, Schumacher B, Neuhaus H, Schmidt C, Wissinowski TT, Nöthen MM, Wellcome Trust Case Control Consortium 2 (WTCCC2), Esophageal Adenocarcinoma Genetics Consortium (EAGLE), Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), Dong J, Ong JS, Buas MF, Thrift AP, Vaughan TL, Tomlinson I, Whiteman DC, Fitzgerald RC, Jankowski J, Vieth M, Mayr A, Gharahkhani P, MacGregor S, Gockel I, Palles C, Schumacher J.) Gut. 2023 Apr;72(4):612-623 PMID: 35882562 SCOPUS ID: 2-s2.0-85135474475 07/27/2022
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation.

(Dong J, Buradagunta CS, Zhang T, Spellman S, Bolon YT, DeZern AE, Gadalla SM, Deeg HJ, Nazha A, Cutler C, Cheng C, Urrutia R, Auer P, Saber W.) J Hematol Oncol. 2023 Mar 10;16(1):21 PMID: 36899395 PMCID: PMC9999628 SCOPUS ID: 2-s2.0-85149930611 03/11/2023
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma.

(D'Souza A, Brazauskas R, Teng BQ, Yun G, Uttley H, Dong J, Dwinell MB, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, Janz S.) Bone Marrow Transplant. 2023 Mar;58(3):334-336 PMID: 36460820 SCOPUS ID: 2-s2.0-85143207078 12/03/2022
FOXM1 regulates glycolysis and energy production in multiple myeloma.

(Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Hari P, Janz S.) Oncogene. 2022 Aug;41(32):3899-3911 PMID: 35794249 PMCID: PMC9355869 SCOPUS ID: 2-s2.0-85133568311 07/07/2022
Admixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis.

(Kim HS, Shetty PB, Tsavachidis S, Dong J, Amos CI, El-Serag HB, Thrift AP.) Clin Gastroenterol Hepatol. 2022 Jun 06 PMID: 35680035 PMCID: PMC9722981 06/10/2022
Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study.

(Buradagunta CS, Garacci Z, D'Souza A, Dhakal B, Devata S, Janz S, Thrift AP, Hari P, Stolley M, Dong J.) Blood Cancer J. 2022 May 25;12(5):82 PMID: 35614050 PMCID: PMC9132975 SCOPUS ID: 2-s2.0-85130720530 05/26/2022
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study.

(Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P.) Blood Cancer J. 2022 Feb 24;12(2):34 PMID: 35210395 PMCID: PMC8873507 SCOPUS ID: 2-s2.0-85125303734 02/26/2022
Impaired Plasma B Cell Markers in CD138+ Cells Predict Prognosis in Multiple Myeloma

(Dong J, Li J, Buradagunta CS, Janz S, Urrutia R, Cheng C.) Blood 2022; 140 (Supplement 1): 10054–10055.. 11/15/2022
Association of Human Leukocyte Antigen Variants with Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

(Massat B, Pareek G, Buradagunta CS, Thapa B, Auer P, Dhakal B, Janz S, Hari P, Dong J.) Blood 2022; 140 (Supplement 1): 10063–10064.. 11/15/2022
WDR26 and MTF2 are therapeutic targets in multiple myeloma.

(Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S.) J Hematol Oncol. 2021 Dec 07;14(1):203 PMID: 34876184 PMCID: PMC8650373 SCOPUS ID: 2-s2.0-85120899924 12/09/2021
A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.

(Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P, Dhakal B.) Cells. 2021 Aug 02;10(8) PMID: 34440730 PMCID: PMC8391934 SCOPUS ID: 2-s2.0-85115041797 08/28/2021
Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study.

(Dong J*, Garacci Z, Buradagunta CS, Mohan M, D'Souza A, Cunningham A, Janz S, Dhakal B, Hari P..) Blood. 11/23/2021

Jing Dong, PhD

Assistant Professor

Locations

Biography

Research Interests

Publications